Remus FY26 PAT rises 20% to ₹46.17 Cr, declares dividend
Remus Pharmaceuticals reported a 37.6% YoY increase in revenue to ₹853.63 Cr for FY26, with PAT growing 20.2% to ₹46.17 Cr. The company declared a final dividend of ₹0.50 per share and expanded into four new markets during H2 FY26.
*this image is generated using AI for illustrative purposes only.
Remus Pharmaceuticals has announced its audited standalone and consolidated financial results for the financial year and half-year ended March 31, 2026. The company reported a significant increase in profitability and operational growth for the full fiscal year, driven by strategic expansion and product launches across international markets. Additionally, the company released an investor presentation detailing its performance highlights and strategic developments for the period.
FY26 Financial Performance
For the full year FY26, the company achieved a revenue from operations of ₹853.63 Cr, compared to ₹620.36 Cr in FY25, representing a year-on-year growth of 37.60%. Profit After Tax (PAT) for the period stood at ₹46.17 Cr, a 20.18% increase from ₹38.42 Cr in the previous year. EBITDA also saw a robust rise of 24.08%, reaching ₹56.69 Cr in FY26 from ₹45.69 Cr in FY25.
Dividend Declaration
The Board of Directors has recommended a final dividend of ₹0.50 per equity share of face value ₹10 each for the financial year 2025-26. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.
H2 FY26 Highlights
The second half of the fiscal year continued the growth trajectory. H2 FY26 revenue reached ₹453.43 Cr, a 30.39% increase compared to ₹347.75 Cr in H2 FY25. Net profit for H2 FY26 rose to ₹24.58 Cr, up 19.51% from ₹20.57 Cr in the corresponding prior period. Sequentially, revenue grew by 13.30% and PAT by 13.86% over H1 FY26 figures.
The following table summarises the consolidated financial performance for FY26 and H2 FY26:
| Metric | FY26 | FY25 | YoY Growth |
|---|---|---|---|
| Revenue | ₹853.63 Cr | ₹620.36 Cr | 37.60% |
| PAT | ₹46.17 Cr | ₹38.42 Cr | 20.18% |
| EBITDA | ₹56.69 Cr | ₹45.69 Cr | 24.08% |
| Metric | H2 FY26 | H2 FY25 | Growth |
|---|---|---|---|
| Revenue | ₹453.43 Cr | ₹347.75 Cr | 30.39% |
| PAT | ₹24.58 Cr | ₹20.57 Cr | 19.51% |
| EBITDA | ₹29.78 Cr | ₹24.52 Cr | 21.45% |
Strategic Developments
During H2 FY26, Remus Pharmaceuticals expanded its commercial presence into four new markets: Myanmar, Nicaragua, North Macedonia, and Madagascar. The company in-licensed key products such as Rifaximin and Fexofenadine for markets including Mexico and Vietnam. It also initiated filings for Semaglutide tablets and injections in emerging markets and secured government tenders in Nicaragua and North Macedonia. The company successfully cleared the Peru DIGEMID audit in February 2026.
Historical Stock Returns for Remus Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.07% | -6.69% | -12.14% | -3.52% | -65.28% | -71.28% |
How will Remus Pharmaceuticals' Semaglutide tablet and injection filings in emerging markets position it competitively against established GLP-1 players, and what revenue contribution could this pipeline deliver by FY28?
Given that PAT growth (20.18%) is lagging behind revenue growth (37.60%), what margin expansion strategies is the company pursuing to improve profitability as it scales international operations?
With successful entry into Myanmar, Nicaragua, North Macedonia, and Madagascar, which new geographies is Remus Pharmaceuticals targeting for commercial expansion in FY27, and how does it plan to fund this growth?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
